Renal effects of environmental and occupational lead exposure

Environmental Health Perspectives

Volumn 105, Issue 9, 1997, Pages 928-938

  Loghman Adham, Mahmoud ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Gout; Heavy metals; Hypertension; Kidney; N acetyl D glucosaminidase; Nephropathy

Indexed keywords

CREATININE; EDETIC ACID; LEAD; LYSOSOME ENZYME; PROTEIN;

AMINOACIDURIA; AUSTRALIA; BLOOD PRESSURE; BODY BURDEN; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; ENVIRONMENTAL EXPOSURE; GLUCOSURIA; GOUT; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; LEAD BLOOD LEVEL; LEAD POISONING; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; REVIEW; UNITED STATES; URINARY EXCRETION; X RAY FLUORESCENCE;

EID: 0030815815     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.2307/3433873     Document Type: Review

References (144)

1. Bernard BP, Becker CE. Environmental lead exposure and the kidney. Clin Toxicol 26:1-34 (1988).
2. Rosen JF. Adverse effects of lead at low exposure levels: trends in the treatment of childhood lead poisoning. Toxicology 97:11-17 (1995).
3. Needleman HL, Gatsonis CA. Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. JAMA 263:673-678 (1990).
4. Goyer RA. Lead toxicity: current concerns. Environ Health Perspect 100:177-187 (1993).
5. Pirkle JL, Brody DJ, Gunter EW, Kramer RA, Paschal DC, Flegal KM, Matte TD. The decline in blood lead levels in the United States. The National Health and Nutrition Surveys (NHANES). JAMA 272:284-291 (1994).
6. Mushak P. Defining lead as the premiere environmental health issue for children in America: criteria and their quantitative application. Environ Res 59:281-309 (1992).
7. Wedeen RP. The role of lead in renal failure. Clin Exp Dialysis Apheresis 6:113-146 (1982).
8. Batuman V. Lead nephropathy, gout, and hypertension. Am J Med Sci 305:241-247 (1993).
9. Olivier AO. De l'albuminurie saturnine. Arch Gen Med (Paris) 2:530 (1863).
10. Nye LJJ. An investigation of the extraordinary incidence of chronic nephritis in young people in Queensland. Med J Aust 2:145-159 (1929).
11. Henderson DA. A follow-up of cases of plumbism in children. Aust Ann Med 3:219-224 (1954).
12. Benett WM. Lead nephropathy. Kidney Int 28:212-220 (1985).
13. Morgan JM, Hartley MW, Miller RE. Nephropathy in chronic lead poisoning. Arch Intern Med 118:17-29 (1966).
14. Wedeen RP, Maesaka JK, Weiner B, Lipat GA, Lyons MM, Vitale LF, Joselow MM. Occupational lead nephropathy. Am J Med 59:630-641 (1975).
15. ATSDR. The Nature And Extent of Lead Poisoning in Children in the United States: A Report to Congress. Atlanta, GA:Agency for Toxic Substances and Disease Registry, 1988.
16. CDC. Preventing lead poisoning in young children. Atlanta, GA:Centers for Disease Control, 1991.
17. Silbergeld EK. Implications of new data on lead toxicity for managing and preventing exposure. Environ Health Perspect 89:49-54 (1990).
18. Elhelu MA, Caldwell DT, Hirpassa WD. Lead in inner-city soil and its possible contribution to children's blood lead. Arch Environ Health 50:165-169 (1995).
19. Bernard AM, Vyskocil A, Roels H, Kriz J, Kodl M, Lauwerys R. Renal effects in children living in the vicinity of a lead smelter. Environ Res 68:91-95 (1995).
20. Campbell BC, Beattie AD, Moore MR, Goldberg A, Reid AG. Renal insufficiency associated with excessive lead exposure. Br Med J 1:482-485 (1977).
21. Goyer RA. Mahaffey KR. Susceptibility to lead toxicity. Environ Health Perspect 2:73-80 (1972).
22. Pollock CA, Ibels LS. Lead nephropathy - a preventable cause of renal failure. Int J Artif Organs 11:75-78 (1988).
23. Pollock CA, Ibels LS. Lead intoxication in industry. Med J Aust 145:635-639 (1986).
24. Ritz E, Wiecek A, Stoeppler M. Lead nephropathy. Contrib Nephrol 55:185-191 (1987).
25. Goyer RA, Krall A, Kimball JP. The renal tubule in lead poisoning: I. Mitochondrial swelling and aminoaciduria. Lab Invest 19:71-77 (1968).
26. Goyer RA. Mechanisms of lead and cadmium nephrotoxicity. Toxicol Lett 46 (1-3):153-162 (1989).
27. Landrigan PJ. Toxicity of lead at low dose. Br J Ind Med 46:593-596 (1989).
28. Nolan CV, Shaikh ZA. Lead nephrotoxicity and associated disorders: biochemical mechanisms. Toxicology 73:127-146 (1992).
29. Angevien JM, Kappas A, DeGowin RL, Spargo B. Renal tubular nuclear inclusion of lead poisoning. Arch Pathol 73:66-74 (1962).
30. Moore JF, Goyer RA, Wilson M. Lead induced inclusion bodies. Solubility, amino acid content, and relationship to residual acidic nuclear proteins. Lab Invest 29:488-494 (1973).
31. Goyer RA, May P, Cates M, Krigman M. Lead and protein content of isolated intranuclear inclusion bodies from kidneys of lead-poisoned rats. Lab Invest 22:245-251 (1970).
32. Vyskocil A, Pancl J, Tusl M, Ettlerova E, Semecky V, Kasparova L, Lauwerys R, Bernard A. Dose-related proximal tubular dysfunction in male rats chronically exposed to lead. J Appl Toxicol 9:395-399 (1989).
33. Cramer K, Goyer RA, Jagenburg R, Wilson MH. Renal ultrastructure, renal function, and parameters of lead toxicity in workers with different periods of lead exposure. Br J Ind Med 31:113-127 (1974).
34. Wilson VK, Thomson ML, Dent CE. Aminoaciduria in lead poisoning. A case in childhood. Lancet 2:66-68 (1953).
35. Goyer RA, Leonard DL, Bream PR, Irons TG. Aminoaciduria in experimental lead poisoning. Proc Soc Exp Biol Med 135:767-771 (1970).
36. Chisolm JJ, Harrison HC, Eberlein WR, Harrison HE. Aminoaciduria, hypophosphatemia, and rickets in lead poisoning. Am J Dis Child 89:159-168 (1955).
37. Chisolm JJ. Aminoaciduria as a manifestation of renal tubular injury in lead intoxication and a comparison with patterns of aminoaciduria seen in other diseases. J Pediatr 60:1-17 (1962).
38. Hammond PB. Exposure of humans to lead. Ann Rev Pharmacol Toxicol 17:197-214 (1977).
39. Waldegger S, Schmidt F, Herzer T, Gukbins E, Schuster A, Biber J, Markovich D, Murer H, Busch AE, Lang F. Heavy metal mediated inhibition of rBAT-induced amino acid transport. Kidney Int 47:1677-1681 (1995).
40. Rosen JF, Chesney RW, Hamstra A, DeLuca HF, Mahaffey KR. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med 302:1128-1131 (1980).
41. Aviv A, Bernstein J, Goldsmith DI, Spitzer A. Lead intoxication during development: its late effects on kidney function and blood pressure. Kidney Int 17:430-437 (1980).
42. Khalil-Manesh F, Gonick HC, Cohen AH, Alinovi R, Bergmaschi E, Mutti A, Rosen VJ. Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney Int 41:1192-1203 (1992).
43. Khalil-Manesh F, Gonick HC, Cohen A, Bergamaschi E, Mutti A. Experimental model of lead nephropathy. II. Effect of removal from lead exposure and chelation treatment with dimethylsuccinic acid (DMSA). Environ Res 58:35-54 (1992).
44. Emmerson BT. Chronic lead nephropathy. Kidney Int 4:1-5 (1973).
45. Nuyts GD, Daelemans RA, Jorens PG, Elseviers MM, Van deVyver FL, DeBroe ME. Does lead play a role in the development of chronic renal disease? Nephrol Dial Transplant 6:307-315 (1991).
46. Chia KS, Mutti A, Alinovi R, Jeyaratnam J, Tan C, Ong CN, Lee E. Urinary excretion of tubular brush border antigens among lead exposed workers. Ann Acad Med Singapore 23:655-659 (1994).
47. Danilovic V. Chronic nephritis due to ingestion of lead-contaminated flour. Br Med J 4:27-28 (1958).
48. Baker EL Jr, Landrigan PJ, Barbour AG, Cox DH, Folland DS, Ligo RN, Throckmorton J. Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead levels. Br J Ind Med 36:314-322 (1979).
49. Pinto de Almeida AR, Carvalho FM, Spinola AG, Rocha H. Renal dysfunction in Brazilian lead workers. Am J Nephrol 7:455-458 (1987).
50. Lilis R, Fischbein A, Valciukas JA, Blumberg W, Selikoff IJ. Kidney function and lead: relationships in several occupational groups with different levels of exposure. Am J Ind Med 1:405-412 (1980).
51. Staessen JA, Lauwerys RR, Buchet J-P, Bulpitt CJ, Rondia D, Vanrenterghem Y, Amery A. Impairment of renal function with increasing blood lead concentrations in the general population. N Engl J Med 327:151-156 (1992).
52. Staessen J, Yeoman WB, Fletcher AE, Markowe HL, Marmot MG, Rose G, Semmence A, Shipley MJ, Bulpitt CJ. Blood lead concentrations, renal function, and blood pressure in London civil servants. Br J Ind Med 47:442-447 (1990).
53. Kim R, Rotnitzky A, Sparrow D, Weiss ST, Wagner C, Hu H. A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. JAMA 275:1177-1181 (1996).
54. Hong CD, Hanenson IB, Lerner S, Hammond PB, Pesce AJ, Pollak VE. Occupational exposure to lead: effects on renal function. Kidney Int 18:489-494 (1980).
55. Cooper WC, Gaffey WR. Mortality of lead workers. J Occup Med 17:100-107 (1975).
56. Malcolm D, Barnett HAR. A mortality of lead workers 1925-1976. Br J Ind Med 39:404-410 (1982).
57. Selevan SG, Landrigan PJ, Stern FB, and Jones JH. Mortality of lead smelter workers. Am J Epidemiol 122:673-683 (1985).
58. Davies JM. Long-term mortality study of chromate pigment workers who suffered lead poisoning. Br J Ind Med 41:170-178 (1984).
59. Verschoor M, Wibowo A, Herber R, van Hemmen J, Zielhuis R. Influence of occupational low-level lead exposure on renal parameters. Am J Ind Med 12:341-351 (1987).
60. Gerhardsson L, Chettle DR, Englyst V, Nordberg GF, Nyhlin H, Scott MC, Todd AC, Vesterberg O. Kidney effects in long-term exposed lead smelter workers. Br J Ind Med 49:186-192 (1992).
61. Greenberg A, Parkinson DK, Puschett JB, Landrigan PJ, Ellis KJ, Wielopolski L, Vaswani AN, Cohn SH. Effects of elevated lead and cadmium burdens on renal function and calcium metabolism. Arch Environ Health 41:69-76 (1986).
62. Chia KS, Jeyaratnam J, Tan C, Ong HY, Ong CN, Lee E. Glomerular function of lead workers. Toxicol Lett 77:319-328 (1995).
63. Buchet JP, Roels H, Bernard A, Lauwerys R. Assessment of renal function of workers exposed to inorganic lead, cadmium or mercury vapor. J Occup Med 22:741-750 (1980).
64. Omae K, Sakurai H, Higashi T, Muto T, Ichikawa M. No adverse effects of lead on renal function in lead-exposed workers. Ind Health 28:77-83 (1990).
65. Emmerson BT. The renal excretion of urate in chronic lead nephropathy. Aust Ann Med 14:295-303 (1965).
66. Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 124:65-76 (1978).
67. Henderson DA, Inglis JA. The lead content of bone in chronic Bright's disease. Aust Ann Med 6:145-154 (1957).
68. Emmerson BT. Chronic lead nephropathy: the diagnostic use of calcium EDTA and the association with gout. Aust Ann Med 12:310-324 (1963).
69. Tepper LB. Renal function subsequent to childhood lead plumbism. Arch Environ Health 7:76-85 (1963).
70. Chisolm JJ. Acute and chronic effects of lead on the kidney. The Lead Conference, Mayaquez, Puerto Rico, 16-18 February 1970. Cited by Goyer RA: Curr Top Pathol 55:147-176 (1971).
71. Moel DI, Sachs HK. Renal function 17 to 23 years after chelation therapy for childhood plumbism. Kidney Int 42:1226-1231 (1992).
72. Hu H. A 50-year follow-up of childhood plumbism. Am J Dis Child 145:681-687 (1991).
73. Payton M, Hu H, Sparrow D, Weiss ST. Low-level lead exposure and renal function in the Normative Aging Study. Am J Epidemiol 140:821-829 (1994).
74. Verberk MM, Willems TEP, Verplanke AJW. Environmental lead and renal effects in children. Arch Environ Health 51:83-87 (1996).
75. McDonald JA, Potter NU. Lead's legacy? Early and late mortality of 454 lead-poisoned children. Arch Environ Health 51:116-121 (1996).
76. Crutcher JC. Clinical manifestations and therapy of acute lead intoxication due to ingestion of illicitly distilled alcohol. Ann Internal Med 59:707-715 (1963).
77. Wright LF, Saylor RP, Cecere FA. Occult lead intoxication in patients with gout and kidney disease. J Rheumatol 11:517-520 (1984).
78. Yu TF. Lead nephropathy and gout. Am J Kidney Dis 5:555-558 (1983).
79. Ludwig GD. Saturnine gout. Arch Intern Med 100:802-812 (1957).
80. Reynolds PP, Knapp MJ, Baraf HS, Holmes EW. Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout. Arthritis Rheum 26:1057-1064 (1983).
81. Ball GV, Morgan JM. Chronic lead ingestion and gout. South Med J 61:21-24 (1968).
82. Ball GV, Sorensen LB. Pathogenesis of hyperuricemia in saturnine gout. N Engl J Med 280:1199-1202 (1969).
83. Wedeen RP, D'Haese P, Van de Vyver FL, Verpooten GA, De Broe ME. Lead nephropathy. Am J Kidney Dis 8:380-383 (1986).
84. Craswell PW. Chronic lead nephropathy. Ann Rev Med 38:169-173 (1987).
85. Goyer RA. Lead and the kidney. Curr Top Pathol 55:147-176 (1971).
86. Batuman V, Maesaka JK, Haddad N, Tepper E, Landy E, Wedeen RP. The role of lead in gout nephropathy. N Engl J Med 304:520-523 (1981).
87. Crasswell PW, Price J, Boyle PD, Heazlewood VJ, Braddeley H, Lloyd HM, Thomas BJ, Thomas BW. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int 26:319-323 (1984).
88. Wedeen R. Lead and the gouty kidney. Am J Kidney Dis 5:559-563 (1983).
89. Batuman V, Landy E, Maesaka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. N Engl J Med 309:17-21 (1983).
90. Pirkle JL, Schwartz J, Landis R, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol 121:246-258 (1985).
91. Hertz-Picciotto I, Croft J. Review of the relation between blood lead and blood pressure. Epidemiol Rev 15:352-373 (1993).
92. Hense HW, Filipiak B, Keil U. The association of blood lead and blood pressure in population surveys. Epidemiology 4:173-179 (1993).
93. deKort WLAM, Verschoor MA, Wilbowo AAE, van Hemmen JJ. Occupational exposure to lead and blood pressure: a study in 105 workers. Am J Ind Med 11:145-156 (1987).
94. dos Santos AC, Colacciopo S, Dal Bo CMR, dos Santos NAG. Occupational exposure to lead, kidney function tests and blood pressure. Am J Ind Med 26:635-643 (1994).
95. Harlan WR, Landis JR, Schmouder RL, Goldstein NG, Harlan LC. Blood lead and blood pressure. Relationship in the adolescent and adult US population. JAMA 253:530-534 (1985).
96. Weiss ST, Munoz A, Stein A, Sparrow D, Speiser FE. The relationship of blood lead to blood pressure in a longitudinal study of working men. Am J Epidemiol 123:800-808 (1986).
97. Wolf C, Wallnofer A, Waldhor T, Vutuc C, Meisinger V, Rudiger HW. Effect of lead on blood pressure in occupationally non-exposed men. Am J Ind Med 27:897-903 (1995).
98. Hu H, Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, Rotnitzky A. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA 275:1171-1176 (1996).
99. Schwartz J. Lead, blood pressure, and cardiovascular disease in men. Arch Environ Health 50:31-37 (1995).
100. Perry HM, Erlanger MW, Perry EF. Increase in the blood pressure of rats chronically fed low levels of lead. Environ Health Perspect 78:107-111 (1988).
101. Victery W. Evidence of effects of chronic lead exposure on blood pressure in experimental animals: an overview. Environ Health Perspect 78:71-76 (1988).
102. Morris C, McCarron DA, Bennet WM. Low-level lead exposure, blood pressure, and calcium metabolism. Am J Kidney Dis 15:568-574 (1990).
103. Lilis R, Gavrilescu N, Nestorescu B, Dumitriu C, Roventa A. Nephropathy in chronic lead poisoning. Br J Ind Med 25:196-202 (1968).
104. Boscolo P, Carmignani M. Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect 78:101-106 (1988).
105. Webb RC, Winquist RJ, Victery W, Vander AJ. In vivo and in vitro effects of lead on vascular reactivity in rats. Am J Physiol 214:H211-H216 (1981).
106. Kopp SJ, Barron JT, Tow JP. Cardiovascular actions of lead and relationship to hypertension: a review. Environ Health Perspect 78:91-99 (1988).
107. Skoczynska A, Juzwa W, Smolic R, Szechinski J, Behal FJ. Response of the cardiovascular system to catecholamines in rats given small doses of lead. Toxicology 39:275-289 (1986).
108. Chai S, Webb RC. Effect of lead on vascular reactivity. Environ Health Perspect 78:85-89 (1988).
109. Fleischer N, Mouw DR, Vander AJ, Sanstead HH. Chronic effects of lead on renin and renal sodium excretion. J Lab Clin Med 95:759-769 (1980).
110. Campbell BC, Meredith PA, Scott JJ. Lead exposure and changes in the renin-angiotensin-aldosterone system in man. Toxicology Lett 25:25-32 (1985).
111. Vander AJ. Chronic effects of lead on the renin-angiotensin system. Environ Health Perspect 78:77-83 (1988).
112. Batuman V, Dreisbach A, Chum E, Naumoff M. Lead increases red cell sodium-lithium countertransport. Am J Kidney Dis 14:200-203 (1989).
113. Cardenas A, Roel H, Bernard AM, Barbon R, Buchet JP, Lauwerys RR, Rosello J, Ramis I, Mutti A, Franchini I. Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br J Ind Med 50:28-36 (1993).
114. Barry PSI, Mossman DB. Lead concentrations in human tissues. Br J Ind Med 27:339-351 (1970).
115. 2 EDTA Pb-mobilization test to detect occult lead nephropathy. Uremia Invest 9(2):127-130 (1985).
116. 2 EDTA provocative test. J Pediatr 104:337-341 (1984).
117. Emmerson BT. Lead stores in patients with renal insufficiency. Nephron 58:233-234 (1991).
118. Weinberger HL, Post EM, Schneider T, Helu B, Friedman J. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child 141:1266-1270 (1987).
119. Treatment guidelines for lead exposure in children. American Academy of Pediatrics Committee on Drugs. Pediatrics 96:155-160 (1995).
120. Fournier L, Thomas G, Garnier R, Buisine A, Houze P, Pradier F, Dolly S. 2,3-dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol 3:499-504 (1988).
121. Mann KV, Travers JD. Succimer, an oral lead chelator. Clin Pharmacol 10:914-922 (1991).
122. Ahlgren L, Mattsson S. An X-ray fluorescence technique for in vivo determination of lead concentration in a bone matrix. Phys Med Biol 24:136-145 (1979).
123. Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, Thomas BJ, Thomas BW, Williams GM. Chronic lead nephropathy in Queensland: alternative methods of diagnosis. Aust NZ J Med 16:11-19 (1986).
124. Wedeen RP, Ty A, Udasin I, Favata EA, Jones KW. Clinical application of in vivo tibial K-XRF for monitoring lead stores. Arch Environ Health 50:355-361 (1995).
125. Hu H, Milder FL, Burger DE. X-Ray fluorescence measurements of lead burden in subjects with low-level community lead exposure. Arch Environ Health 45:335-341 (1990).
126. Price J, Grudzinski AW, Craswell PW, Thomas BJ. Repeated bone lead levels in Queensland, Australia - previously a high lead environment. Arch Environ Health 47:256-262 (1992).
127. Price J, Grudzinski AW, Craswell PW, Thomas BJ. Bone lead measurements in patients with chronic renal disease studied over time. Arch Environ Health 47:330-335 (1992).
128. Sommervaille LJ, Chettle DR, Scott MC. In vivo measurement of lead in bone using X-ray fluorescence. Phys Med Biol 30:929-943 (1985).
129. Landrigan PJ, Todd AC. Direct measurement of lead in bone: a promising biomarker. JAMA 271:239-240 (1994).
130. Wedeen RD. In vivo tibial XRF measurement of bone lead. Arch Environ Health 45:69-71 (1990).
131. Sokas RK, Besarb A, McDiarmid MA, Shapiro IM, Bloch P. Sensitivity of in vivo X-ray fluorescence determination of skeletal lead stores. Arch Environ Health 45:268-272 (1990).
132. Todd AC, McNeil FE, Fowler BA. In vivo X-ray fluorescence of lead in bone. Environ Res 59:326-335 (1992).
133. Bernard A, Lauwerys R. Epidemiologic application of early markers of nephrotoxicity. Toxicol Lett 46:298-306 (1989).
134. Konishi Y, Endo G, Kiyota A, Horiguchi S. Fractional clearance of low molecular weight proreins in lead workers. Ind Health 32:119-127 (1994).
135. Meyer BR, Fischbein A, Rosenman K, Lerman Y, Drayer DE, Reidenberg MM. Increased urinary enzyme excretion in workers exposed to nephrotoxic chemicals. Am J Med 76:989-998 (1984).
136. Endo G, Horiguchi S, Kiota I. Urinary N-acetyl-β-glucosaminidase activity in lead-exposed workers. J Appl Toxicol 10:325-328 (1990).
137. Khalil-Manesh F, Gonick HC, Cohen AH. Experimental model of lead nephropathy. III. Continuous low-level lead administration. Arch Environ Health 48:271-278 (1993).
138. Chia KS, Mutti A, Tan C, Ong HY, Jeyaratnam J, Ong CN, Lee E. Urinary N-acetyl-β-D-glucosaminidase activity in workers exposed to inorganic lead. Occup Environ Med 51:125-129 (1994).
139. Kumar BD, Krishnanaswamy K. Detection of occupational lead nephropathy using early renal markers. Clin Toxicol 33:331-335 (1995).
140. Lin JL, Yeh KH, Tseng HC, Chen WY, Lai HH, Lin YC. Urinary N-acetyl-glucosaminidase excretion and environmental lead exposure. Am J Nephrol 13:442-447 (1993).
141. Fels LM, Herbort C, Pergande M, Jung K, Hotter G, Rosello J, Gelpi E, Mutti A, De Broe M, Stolte H. Nephron target sites in chronic exposure to lead. Nephrol Dial Transplant 9:1740-1746 (1994).
142. Pergande M, Jung K, Precht S, Fels LM, Herbort C, Stolte H. Changed excretion of urinary proteins and enzymes by chronic exposure to lead. Nephrol Dial Transpl 9:613-618 (1994).
143. Chia KS, Jeyaratnam J, Lee J, Tan C, Ong HY, Ong CN, Lee E. Lead induced nephropathy: relationship between various biological exposure indices and early markers of nephrotoxicity. Am J Ind Med 27:883-895 (1995).
144. Radosevic Z, Saric M, Beritic T, Knezevic J. The kidney in lead poisoning. Br J Ind Med 18:222-230 (1961).